Flatiron Health Review
VisitOncology data and technology to accelerate cancer research
Flatiron Health is a healthcare technology company providing oncology-focused data and software solutions.
AI Panel Score
8.2/10
6 AI reviews
Reviewed
Oncology data and technology to accelerate cancer research
Flatiron Health is a healthcare technology company providing oncology-focused data and software solutions.
AI Panel Score
6 AI reviews
Reviewed
Flatiron Health is a New York-based healthcare technology company specializing in oncology. It operates two interconnected business lines: a cloud-based oncology electronic health record (EHR) platform called OncoEMR, used by community cancer clinics and academic medical centers, and a real-world data (RWD) business that aggregates and structures de-identified patient data from its clinical network for use in research and regulatory submissions.
The OncoEMR platform is built specifically for oncology workflows, supporting clinicians with treatment planning, chemotherapy order management, clinical trial matching, and quality reporting. Unlike general-purpose EHR systems, it is tailored to the complex and iterative nature of cancer care, including regimen management and structured data capture at the point of care.
On the research side, Flatiron's real-world data products are used by biopharmaceutical companies, academic researchers, and regulatory agencies including the U.S. Food and Drug Administration (FDA). These datasets are derived from longitudinal patient records and include information on diagnoses, treatments, outcomes, and biomarkers. The structured nature of this data makes it useful for generating evidence to support drug development, label expansions, and health economics research.
Flatiron Health was acquired by Roche in 2018, giving it deep ties to one of the largest oncology-focused pharmaceutical companies in the world. Despite the acquisition, Flatiron maintains a degree of operational independence and continues to serve a broad range of clients across the oncology ecosystem.
The company occupies a distinct position in the health technology market by focusing exclusively on oncology, combining a clinical software business with a data and analytics business. This dual model allows it to continuously enrich its real-world dataset through active clinical use, a key differentiator from data vendors that rely solely on claims or secondary data sources.
Uses large language models and AI to extract nuanced clinical information from unstructured data sources, including real-world patient records for research purposes.
Builds digital twin models that simulate patient outcomes under different treatment scenarios, as showcased in recent research acceptances at ISPOR 2026.
Partners with organizations like the Community Oncology Alliance to conduct comprehensive real-world assessments of cancer care quality and patient outcomes across community practices.
Offers access to 5 million+ de-identified patient records available for oncology research, enabling large-scale real-world data studies.
Delivers actionable data and treatment insights directly at the point of care, enabling clinicians to make informed, evidence-based decisions during patient encounters.
Provides fit-for-purpose real-world evidence by partnering with Flatiron's team of clinicians, scientists, and health data analysts to generate robust evidence and insights for oncology research goals.
Provides real-world clinical data and evidence solutions to biopharma and regulatory bodies to accelerate oncology drug development and market access.
A decision support tool that helps clinicians choose and find appropriate treatment regimens for cancer patients while staying within NCCN guidelines, with customizable treatment plans.
An oncology-specific EHR platform designed with instinctive workflows to improve the patient experience, streamline operations, and increase revenue for oncology practices.
A precision oncology platform with customizable clinical decision support that incorporates up-to-date treatment guidelines and actionable data at the point of care.
Cloud-based oncology EHR and practice management platform for community cancer practices. Pricing is not publicly listed and requires contacting Flatiron Health's sales team for a custom quote.
Real-world evidence datasets and research services for life sciences companies, biopharma, and academic research centers. Pricing requires a custom contract negotiated directly with Flatiron's partnerships team.
EHR-integrated platform for identifying, screening, recruiting, and tracking eligible oncology patients for clinical trials. Custom pricing available via Flatiron sales.
Roche-backed, FDA-trusted, 5M patient records — oncology's infrastructure play.
“Flatiron owns the oncology data layer that biopharma and regulators already depend on. If you're in cancer care or drug development, this isn't optional infrastructure — it's the category.”
Acquired by Roche in 2018. FDA uses their data. 5 million de-identified patient records from 280+ community practices. Vendor viability isn't a question here — it's one of the strongest backstops in health tech. That's a rare thing to say with confidence.
The dual model is what makes this defensible. OncoEMR captures structured clinical data at the point of care, which continuously enriches the research dataset. Competitors like Tempus or Foundation Medicine work from genomic angles; Flatiron's moat is longitudinal real-world outcomes. The 44% reduction in unique regimens via Flatiron Assist is a concrete clinical win, not a marketing stat.
The tradeoff: pricing is fully opaque, contact-only, no tiers. Budget conversations with the board will be awkward until you've signed. And the platform is oncology-only — if your scope ever widens beyond cancer care, you're buying a second system.
Tempus and Foundation Medicine compete on genomics; Flatiron's longitudinal real-world outcomes dataset at 5M+ records is a structural lead in regulatory-grade evidence.
FDA uses their data; the Community Oncology Alliance partners with them — this is a board-defensible choice with zero credibility risk.
Contact-only pricing and custom contracts mean slow procurement; the 44% regimen reduction stat suggests real clinical ROI once deployed, but the path there isn't fast.
The OncoEMR-to-RWD flywheel advances both clinical operations and research capability simultaneously — this isn't a cost-save, it's infrastructure.
Roche acquisition (2018) plus active FDA partnership makes this one of the most stable vendor bets in health tech.
Biopharma, cancer research centers, or community oncology practices that need regulatory-grade real-world evidence or oncology-specific clinical workflows.
You need a general-purpose EHR or your oncology scope is too small to justify a full enterprise contract negotiation.
Oncology-native data infrastructure with FDA credibility that generalists can't replicate.
“Flatiron runs a dual-engine model — OncoEMR captures structured point-of-care data, and that same data feeds a 5 million+ patient RWD asset used by biopharma and regulators. That flywheel is the moat.”
Flatiron Assist's 44% reduction in unique regimens ordered is a clinical quality signal, not just a product metric. NCCN-aligned decision support embedded in workflow — not bolted on as an afterthought — reflects someone who understands how community oncologists actually practice. The digital twin modeling accepted at ISPOR 2026 suggests the research product is pushing toward outcomes simulation, which is where serious biopharma partnerships are heading.
The Roche acquisition in 2018 is the central strategic fact. It creates deep oncology credibility and sustained investment, but any CMO considering this for RWD partnerships needs to think about data governance optics — competitors like Veeva Vault or COTA will raise the question in every procurement conversation.
No public pricing and no free trial means this isn't a self-serve evaluation. If your institution needs a rapid pilot, that's a real friction point. But if you're a cancer center or biopharma team making a 3-year infrastructure commitment, the depth here — 280+ community practices, 7+ academic centers, FDA-used datasets — is hard to assemble elsewhere.
FDA reliance on Flatiron's RWD for regulatory submissions puts it in a category position that Syapse, COTA, and Veeva simply haven't reached at equivalent scale.
OncoEMR and Flatiron Assist are built around regimen management and chemotherapy ordering — workflows that break inside general-purpose EHRs like Epic's oncology modules.
HL7 interoperability is documented and the clinical trial recruitment platform integrates directly with OncoEMR, but no public API docs limit visibility into third-party connectivity depth.
If you adopt OncoEMR, in 3 years your structured data is contributing to and accessible through one of the most credentialed oncology RWD assets in existence — that's leverage, not lock-in anxiety.
Dual-model combining live clinical EHR capture with longitudinal RWD creates compounding data quality that pure claims-based vendors can't match.
Cancer centers and biopharma teams making a long-cycle oncology data infrastructure commitment where regulatory-grade RWD matters.
Your institution needs a rapid self-serve pilot or a vendor with no pharma ownership in the data chain.
5 million patient records, zero published prices — budget blind until contract signed
“Flatiron Health runs two enterprise business lines: an oncology EHR (OncoEMR) and a real-world data operation serving biopharma and the FDA. Every pricing tier is contact-only, making TCO modeling impossible without a sales process.”
No pricing page. Three product lines, three custom quotes. OncoEMR, the RWD research suite, and the clinical trial recruitment platform all require a sales call. Category norm for enterprise EHR — but that doesn't make it procurement-friendly. Expect 6-12 month sales cycles and multi-year contracts. Budget blind until you're deep in negotiation.
The 5 million+ de-identified patient records are the real asset. Biopharma pays for RWD access; the EHR network feeds the dataset continuously. That flywheel is the moat. Flatiron Assist showed a 44% reduction in unique regimens ordered — that's a defensible ROI number for hospital system buyers. Compare to Veeva Vault or Medidata on the research side: Flatiron's oncology depth is narrower but denser.
Roche ownership since 2018 adds a conflict-of-interest question every procurement team should raise. Data exclusivity terms and audit rights belong in any contract. No changelog, no API docs visible — integration costs are unknown and likely significant.
Custom contracts on all three lines, Roche parent adds vendor risk review, and no API docs means integration scoping is a separate cost.
No public terms; enterprise EHR category norm is 3-5 year agreements with limited termination-for-convenience clauses.
Zero published prices across all three product lines; contact-only across the board.
44% regimen reduction stat and FDA-accepted RWD submissions give biopharma and clinical buyers concrete value anchors.
Multi-year enterprise contracts, unknown integration costs, and no published overage rates make 3-year TCO unmodelable pre-contract.
Biopharma teams running late-phase oncology trials or community cancer practices needing an oncology-native EHR with NCCN-aligned decision support.
Your procurement team needs a price before a discovery call or your legal team won't clear a Roche-affiliated data vendor.
Oncology-native EHR plus 5 million patient records — purpose-built, not repurposed
“Flatiron Health does one thing: oncology. OncoEMR plus Flatiron Assist plus a real-world data pipeline built from 280+ community practices is a stack no general-purpose EHR vendor can replicate. The tradeoff is opacity — no public pricing, no changelog, no API docs visible.”
Flatiron Assist's 44% reduction in unique regimens ordered is the number that matters at the clinic level. That's not a marketing stat — that's standardization you feel every Tuesday when a new fellow orders a one-off regimen. NCCN-aligned decision support baked into the order workflow, not bolted into a sidebar, is exactly the kind of thing Epic or Cerner will never prioritize the way an oncology-native vendor will.
The dual model — active clinical use feeding the RWD pipeline — is genuinely differentiated. Claims-only vendors like Komodo or Symphony Health are working from billing codes. Flatiron's 5 million de-identified records come from structured point-of-care capture. For a community practice, that also means your documentation is contributing to research you can actually cite. The clinical trial matching feature inside OncoEMR could move patient identification from a coordinator spreadsheet to the encounter itself.
The friction surfaces are real though. No public changelog means you hear about updates in release notes or not at all. No API docs visible publicly suggests integration lift is a conversation, not a self-serve process. For academic centers already running Epic, the interoperability story matters more than the docs indicate.
Oncology-specific workflows including regimen management and Flatiron Assist reduce the daily fights clinicians face in general-purpose EHRs like Epic.
No public docs portal visible; the website reads as positioning for buyers, not a reference for daily users troubleshooting a workflow.
No public API docs or changelog means integration questions create support dependency rather than self-service resolution.
Customizable clinical decision support platform and clinical trial matching suggest real depth for advanced oncology workflows, backed by a 5M+ record dataset for researchers.
Point-of-care insights and NCCN-aligned decision support are embedded in the chart flow, not separate tools requiring context switching.
Community oncology practices and cancer centers wanting an oncology-native EHR that doubles as a research data contributor.
Your institution is already deep in Epic and needs a vendor whose integration playbook is self-serve and documented.
Five million patient records and an FDA relationship — that's not a demo, that's a moat
“Flatiron does something almost no one else does: owns both the clinical workflow and the research data pipeline in oncology. That dual model, built over years and 280+ community practices, is genuinely hard to replicate.”
OncoEMR isn't trying to be Epic. It's not trying to be anybody but an oncologist's daily driver — regimen management, NCCN-aligned treatment planning via Flatiron Assist, clinical trial matching baked right in. That 44% reduction in unique regimens ordered is a real number, not a vanity metric. That's what happens when the software actually knows the domain.
The real-world data side is where things get interesting for anyone not at a cancer clinic. Five million de-identified patient records, FDA submissions, biopharma partnerships — this is infrastructure-level stuff. The digital twin modeling showcased at ISPOR 2026 suggests the AI layer is genuinely advancing, not just a buzzword in the marketing deck.
The tradeoff: there's no pricing page, no trial, no self-serve anything. This is a sales-call-required, contract-negotiated product. Fine for health systems and pharma. Brutal if you're a smaller research org trying to size budget. Compared to something like Veeva, which at least gives you product tiers to anchor against, Flatiron keeps its cards close.
OncoEMR is described as having instinctive oncology workflows and point-of-care insights, but no changelog or public UX evidence makes it hard to know if the details are sweated daily.
Oncology-specific design and Flatiron Assist's NCCN guideline alignment should help clinicians get oriented, but the depth of the RWD platform likely demands significant onboarding time for research users.
Listed platform is web-only; no mobile app evidence in the scraped data, which for a clinical tool used at the point of care is a real gap.
No free trial, no self-serve, no pricing page — first contact is a sales call, which means onboarding starts with homework, not welcome.
Roche-backed, FDA-trusted, running across 280+ community practices — the reliability bar here is regulatory-grade, which is about as serious as it gets.
Community oncology practices, biopharma research teams, and academic cancer centers that need a purpose-built clinical and evidence platform.
You need transparent SaaS pricing or a fast self-serve evaluation path before committing budget.
5 million records and FDA buy-in. Hard to fake either.
“Flatiron's dual-model — live EHR feeding a research dataset — is structurally hard to replicate. Roche ownership since 2018 removes the 'will they survive?' question almost entirely.”
Three tells that made me take this seriously. One: 44% reduction in unique regimens ordered via Flatiron Assist — that's a specific operational outcome, not a vibe. Two: FDA actually uses the data. Regulatory adoption is a moat most competitors never clear. Three: 5 million+ de-identified records sourced from active clinical use, not claims scraping. That's structurally different from Tempus or Syapse.
Two flags. Exit portability is rough. OncoEMR lock-in at a community cancer practice is deep — workflows, billing, regimen history. Migrating to Epic or Veeva Vault is a multi-year pain event. Also: no pricing page, no API docs visible, no changelog. Opacity is category-normal for enterprise health IT, but still a yellow.
Viability concern is basically zero. Roche acquired in 2018 and hasn't unwound it. Digital twin modeling accepted at ISPOR 2026 shows active R&D. This isn't vaporware. It's boring infrastructure — which is exactly what oncology needs.
Live-EHR-to-research-dataset flywheel separates it from claims-based vendors like Tempus or Optum; FDA-validated RWD is a narrow moat.
OncoEMR is deep workflow lock-in; structured regimen history and billing data don't migrate cleanly to Epic or any general EHR.
Roche ownership, ISPOR 2026 research acceptances, and 280+ community practice network suggest a well-resourced, actively shipping platform.
'Reimagining the infrastructure' is aspirational but the landing copy is grounded in regulatory use and clinical outcomes, not buzzword salad.
FDA adoption, Roche backing since 2018, and a named 44% regimen reduction outcome — matches patterns of durable health IT platforms, not failed ones.
Biopharma RWE teams, community oncology practices, and academic cancer centers needing regulatory-grade longitudinal data.
You need transparent pricing, easy integration docs, or a clean exit path within 18 months.
Common questions answered by our AI research team
Flatiron Health has 5 million+ de-identified patient records available for research.
Flatiron Assist is a clinical decision support tool that helps clinicians select appropriate treatment regimens, stay within NCCN guidelines, and build robust, customizable treatment plans.
Yes, Flatiron partners with expert clinicians, scientists, and health data analysts to help biopharma and other organizations generate robust real-world evidence and insights for oncology.
Yes, cancer centers using Flatiron Assist saw a 44% reduction in the number of unique regimens ordered, indicating meaningful standardization of treatment across practices.
Yes, Flatiron's real-world data is used by biopharma and regulatory bodies as part of its real-world data business.
Flatiron Health is a New York-based healthcare technology company that builds software and data products for cancer research and care.
